Infliximab (Remicade)

06/22/2014 - "Colonoscopy performed after the third infliximab showed remarkable improvement in the ileocolitis. "
11/01/2013 - "The infliximab (IFX) has dramatically improved the treatment of Crohn's disease (CD). "
12/01/2007 - "Infliximab is well-tolerated and highly effective in achieving clinical remission in children with refractory Crohn's disease but may only delay and not avoid the need for surgery. "
01/01/2005 - "Although infliximab is highly effective in the treatment of Crohn's disease (CD), attenuated response to infliximab may develop over time in a subgroup of patients. "
11/01/2004 - "Treatment with infliximab is well tolerated and effective in most children and adolescents with Crohn's disease that is refractory to conventional immunosuppressive therapy. "

01/01/2022 - "Background: Infliximab (IFX) is a potent therapeutic agent used for the treatment of conventional refractory ulcerative colitis (UC). "
02/01/2017 - "Long-term efficacy of infliximab treatment in chronic active ulcerative colitis is excellent especially in patients who respond to induction treatment. "
09/20/2009 - "Besides, infliximab is potent in the remission and its sustaining in ulcerative colitis. "
06/01/2006 - "[Infliximab in active ulcerative colitis -- proven efficacy as induction and maintenance treatment]."
08/01/2001 - "Infliximab appears to be a potent agent for inducing remission in refractory patients with ulcerative colitis."

08/01/2009 - "The use of biologicals such as infliximab has dramatically improved the treatment of rheumatoid arthritis (RA). "
01/01/2017 - "The Infliximab, has proven effective in treating rheumatoid arthritis (RA). "
04/17/2017 - "BACKGROUND Infliximab shows good efficacy in treating refractory rheumatoid arthritis (RA). "
06/01/2009 - "Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab."
01/01/2002 - "Infliximab is effective in a significant number of patients with severe rheumatoid arthritis, with a good tolerability."

11/01/2016 - "Infliximab in the Australian context has proven to be a highly effective treatment of chronic plaque psoriasis, and patients who remained on the drug derived a high level of satisfaction, assessed both subjectively (DLQI) and objectively (PASI 75). "
02/01/2014 - "This suggests that while the management of psoriasis patients with comorbid conditions and various unfavorable prognostic characteristics requires a multidisciplinary approach to ensure the patient obtains the best therapeutic response, infliximab is an effective and well tolerated treatment in these patients."
01/01/2009 - "Infliximab appears to be the most effective treatment for nail psoriasis to date."
06/01/2003 - "Scientists noticed the marked skin improvement of this patient and later demonstrated the efficacy of infliximab for psoriasis in a randomized, double-blind, placebo-controlled trial. "
12/01/2011 - "Infliximab is very effective in the treatment of psoriasis either with nail involvement and/or PsA. "

01/01/2018 - "The Trough Concentration Adapted Infliximab Treatment (TAXIT) trial demonstrated that maintaining infliximab trough concentrations at 3 to 7 μg/mL is most effective at inducing remission in patients with inflammatory bowel diseases (IBDs), with fewer flares than clinic-based dosing. "
02/18/2021 - "High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study."
01/01/2019 - "Therapeutic drug monitoring (TDM) of infliximab (IFX) appears to be beneficial for patients with inflammatory bowel disease (IBD). "
08/01/2016 - "Infliximab, the first anti-TNF-α biologic drug, has significantly improved inflammatory bowel disease (IBD) treatment outcomes by preventing structural damage progression, thereby reducing complications and the need for surgery and hospitalization. "
02/01/2016 - "The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease."